相关实验视频

Updated: Jan 11, 2026

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

免疫疗法耐药性模型的构建和应用方面的研究进展

Huiling Li¹, Shenzhan Wang², Xiaoxi Li¹

¹Department of Pharmacy, Xuanwu Hospital, Capital Medical University, Beijing, 100053, China.

Cancer immunology, immunotherapy : CII

|November 18, 2025

概括

免疫疗法耐药性模型对于理解和克服治疗挑战至关重要. 本综述详细介绍了它们的构建和应用,以提高癌症免疫疗法的疗效和开发新药.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
药物开发药物开发

背景情况:

免疫疗法已经彻底改变了癌症治疗,但抗药性仍然是一个重大的临床挑战.
了解免疫疗法耐药性的机制对于改善患者的治疗结果至关重要.
目前研究免疫疗法耐药性的模型需要进一步改进,以更好地模仿临床情景.

研究的目的:

综合审查免疫疗法耐药性模型的构建方法和应用.
讨论现有模型的特征特征和潜在的阻力机制.
确定开发改进模型的策略,以回顾临床环境.

主要方法:

对涉及免疫疗法耐药性模型的研究进行系统文献综述.
模型特征的分析,包括体外,体内和体外系统.
讨论通过这些模型识别的抵抗机制.

主要成果:

已建立的免疫疗法耐药性模型是理解耐药性机制的关键工具.
这些模型有助于模拟和解决与免疫治疗药物耐药性相关的临床挑战.
该审查强调了模型选择对于验证药物有效性和安全性的重要性.

结论:

需要进一步开发免疫疗法耐药性模型,以更好地反映临床现实.
来自精细模型的机械洞察力可以增强免疫疗法灵敏度.
改进的模型将促进新型抗瘤剂和治疗策略的发展.

关键词:

免疫疗法耐药性模型免疫疗法耐药性的机制模型应用程序模型应用程序模型特征模型特征建立模型的战略建立模型的战略

更多相关视频

Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry

Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry

Published on: October 9, 2018

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...